News
1d
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...
The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...
It became clear over the first quarter that the amount of business that had gone to the compounders was just significantly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback